TRX BioSurgery wins GPO Supplier Horizon Award

RNS Number : 1009S

Tissue Regenix Group PLC

21 June 2018

 

Tissue Regenix Group plc

TRX BioSurgery recognised at Premier, Inc Breakthrough Awards

Leeds, 21 June 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that TRX BioSurgery has been awarded the Supplier Horizon Award by the Group Purchasing Organization, Premier, Inc. ("Premier") at their Breakthrough conference taking place currently in Nashville, Tennessee.

The Supplier Horizon Award recognizes suppliers that have been contracted with Premier for less than three years for exceptional local customer service and engagement, value creation through clinical excellence and commitment to lower costs. Notably the awards are voted upon by Premier members who have the first-hand experience of the products being used in clinical settings.

TRX BioSurgery was originally recognized by the GPO in 2016 when its' decellularized dermal allograft 'DermaPure' was awarded an 'Innovative Technology Award'  by the GPO after a thorough four step review process determined that the technology offers unique attributes when compared to the other available treatment options.

Steve Couldwell, CEO, Tissue Regenix Group commented: "We are delighted to receive the Premier Horizon award.  It again highlights not only the differentiated clinical outcomes from the use of DermaPure, but also the health economic advantages of its' single application in many hospital settings.  Being acknowledged by Premier's member institutions for such an award re affirms our value proposition in the space, and we look forward to continuing to establish these relationships."

For more Information:

Tissue Regenix Group plc Caitlin Pearson                                 Head of Communications	Tel: [phone] /  07920272 441
Jefferies International Ltd Simon Hardy / Christopher Binks	Tel:  [phone]
FTI Consulting  Brett Pollard / Mo Noonan/ Rob Winder	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

NRAGUGDLIXDBGIB